<DOC>
	<DOCNO>NCT01341717</DOCNO>
	<brief_summary>The purpose study determine efficacy safety sitaglipin treatment Type 2 diabetes mellitus ( T2DM ) patient inadequate glycemic control use metformin insulin .</brief_summary>
	<brief_title>Effects Sitagliptin Type 2 Diabetes Mellitus Patients Treatment With Metformin Insulin</brief_title>
	<detailed_description>DPP-4 inhibitor enhance function endogenous incretin help glucose homoeostasis . DPP-4 inhibitor prove promote glycemic control without increase risk hypoglycemia weight gain . In addition , may improve beta-cell function know association overt cardiovascular hepatic safety risk . Addition sitagliptin treatment T2DM patient poorly control insulin +/- metformin show reduce HbA1c generally well-tolerated . It could clinically useful add sitaglipin treatment regimen T2DM patient stable therapy insulin &amp; metformin . Apart glycemic reduction , secondary effect like prevention weight gain , reduction insulin dose , improve cardiovascular risk profile , etc . may expect addition sitagliptin treatment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>T2DM patient metformin biphasic basal regimens insulin HbA1c ≥7.3 % ≤8.5 % Age : 25 60 yrs Insulin TDD &gt; 10 IU Use acarbose , pioglitazone shortacting insulin analogue time runin phase History type 1 diabetes mellitus Creatinine clearance ≤50 mL/min Chronic liver &amp; kidney disease , SGOT/PT≥2.5x upper limit normal , uncontrolled thyroid disorder , cardiac failure , hemochromatosis , autoimmune disorder , corticosteroid intake . BMI &gt; 40 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>Insulin</keyword>
</DOC>